Elan: The Virtues of the Middle

Big Pharma's growth problems are horrendous; biotech's a crapshoot. Much to everyone's surprise, mid-sized drug companies may have the most options. Having done four modest acquisitions since 1986, Elan has transformed itself and, in the process, shown how middle tier companies can take advantage of licensing and acquisition opportunities big companies can't touch.